Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 22;30(1):100-109.
doi: 10.3390/curroncol30010008.

Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC)

Stéphanie L Mercier  1 , Sara M Moore  1   2 , Deborah Akurang  2 , David Tiberi  2   3 , Paul Wheatley-Price  1   2
Affiliations

Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC)

Stéphanie L Mercier et al. Curr Oncol. .

Abstract

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumour with metastatic propensity. Stereotactic body radiation therapy (SBRT) is an emerging therapeutic option for SCLC, despite limited supporting evidence. By evaluating the use of SBRT in very limited stage (VLS) SCLC at our institution, we aimed to contribute to the existing knowledge in this area while establishing a basis for further research. We performed a retrospective review of all cases of VLS-SCLC treated with SBRT between 2013 and 2020. Baseline demographics, diagnostic, and treatment information were collected. The primary outcome was overall survival (OS). We identified 46 patients with pathologically confirmed VLS-SCLC; 25 were treated with SBRT, and the remainder received either surgery, conventional radiation therapy, chemotherapy, or palliative-intent therapy. After a median follow-up of 23.7 months, 44% of the patients had died; the median OS was of 24.4 months for the SBRT cohort and 67.0 months for the curative intent non-SBRT cohort. The difference in disease recurrence and survival between cohorts was underpowered and not statistically significant. Higher baseline ECOG and comorbidity was noted in the SBRT cohort.

Keywords: SABR; SBRT; SCLC; limited stage.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overall survival (OS) comparing SBRT and curative-intent non-SBRT (surgery and conventional RT) cohorts.
Figure 2
Figure 2
Cumulative incidence of death or recurrence versus death.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Canadian Cancer Statistics Advisory Committee Lung Cancer Statistics. 2021. [(accessed on 17 December 2021)]. Available online: https://cancer.ca/en/cancer-information/cancer-types/lung/statistics.
    1. American Cancer Society What is Lung Cancer? 2019. [(accessed on 17 December 2021)]. Available online: https://www.cancer.org/cancer/lung-cancer/about/what-is.html.
    1. American Cancer Society Small Cell Lung Cancer Causes, Risk Factors, and Prevention. 2016. [(accessed on 19 December 2021)]. Available online: https://www.cancer.org/content/dam/CRC/PDF/Public/8709.00.pdf.
    1. American Cancer Society Treating Small Cell Lung Cancer. 2021. [(accessed on 19 December 2021)]. Available online: https://www.cancer.org/content/dam/CRC/PDF/Public/8711.00.pdf.
    1. Micke P., Faldum A., Metz T., Beeh K.-M., Bittinger F., Hengstler J.G., Buhl R. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease? Lung Cancer. 2002;37:271–276. doi: 10.1016/S0169-5002(02)00072-7. - DOI - PubMed

MeSH terms